Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Jan-Dec:18:17539447241289067.
doi: 10.1177/17539447241289067.

Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis

Abdulrahman Khaldoon Hamid  1 , AbdulJaber A'Ed Tayem  2 , Sandra Thair Al-Aish  3 , Ahmed Sermed Al Sakini  3 , Dalia Dhia Hadi  4 , Rami Thair Al-Aish  3
Affiliations
Meta-Analysis

Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis

Abdulrahman Khaldoon Hamid et al. Ther Adv Cardiovasc Dis. 2024 Jan-Dec.

Abstract

Background: Heart failure (HF) is a highly prevalent disease, among the primary factors contributing to morbidity and death. One of its types is heart failure with preserved ejection fraction (HFpEF) comprising 40%-50% of newly diagnosed HF cases. Despite the high prevalence of HFpEF, there is still a lack of knowledge regarding the best drugs and treatment approaches to be used. However, the sodium-glucose co-transporter 2 (SGLT2) inhibitors could be a promising treatment.

Objectives: To examine SGLT2 inhibitors' effect on hospitalization, cardiovascular death, and estimated glomerular filtration rate (eGFR) in HFpEF patients.

Search methods: We conducted searches for randomized controlled trials (RCTs) in PubMed, Embase, Scopus, and Web of Science up to July 2024.

Selection criteria: We chose RCTs that examined the effects of SGLT2 inhibitors and placebo in individuals with higher than 40% ejection fraction (HFpEF).

Data collection and analysis: The methodology for the systematic review and meta-analysis was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis.

Main results: We included 8 studies with 16,509 participants. Drugs examined in our paper included empagliflozin, dapagliflozin, sotogliflozin, and ertugliflozin. Various outcomes were analyzed in different papers. However, different SGLT2 inhibitors lead to a decreased risk of cardiovascular hospitalization and kidney injury. Our meta-analysis showed a decreased risk of cardiovascular hospitalization but not death due to cardiovascular causes or other causes. These results were regardless of baseline status of eGFR, systolic blood pressure, atrial fibrillation or flutter, diabetes mellitus, sex, body mass index, and nt-proBNP. The included studies were of moderate to high quality.

Conclusion: For individuals with HFpEF, SGLT2 inhibitors have been proven to be a safe and effective medication. However, more studies are needed for longer durations, reporting adverse events, effects on exercise tolerance, and other secondary outcomes.

Keywords: SGLT2 inhibitors; cardiovascular death; dapagliflozin; empagliflozin; ertugliflozin; estimated glomerular filtration rate (eGFR); heart failure with preserved ejection fraction (HFpEF); hospitalization; quality of life; sotagliflozin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Diagram showing the flow of the PRISMA. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. *Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).For a detailed overview of the study’s methodology, please refer to the PRISMA checklist in the Supplemental Material.
Figure 2.
Figure 2.
Quality assessment of RCT using the Cochrane assessment tool. RCT, randomized controlled trial.
Figure 3.
Figure 3.
A forest plot comparing the risk of outcomes for patients with HFpEF in response to SGLT2 inhibitors against a placebo. The forest plot displays the hazard ratios of SGLT2 inhibitors in patients with HFpEF in comparison to a placebo. Cardiovascular death or hospitalization for heart failure; cardiovascular death; heart failure hospitalization; all-cause death. (a) Main outcomes and (b) secondary outcomes. HFpEF, heart failure with preserved ejection fraction; SGLT2, sodium-glucose co-transporter 2.
Figure 4.
Figure 4.
Forest plot for prespecified analysis of main outcomes.
Figure 5.
Figure 5.
Summary outcomes of empagliflozin in HFpEF. Source: GMAD; GDJ. HFpEF, heart failure with preserved ejection fraction.
See this image and copyright information in PMC

References

    1. McMurray JJV, Pfeffer MA. Heart failure. Lancet 2005; 365(9474): 1877–1889. - PubMed
    1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390(10100): 1151–1210. - PMC - PubMed
    1. Shahim B, Kapelios CJ, Savarese G, et al.. Global public health burden of heart failure: an updated review. Card Fail Rev 2023; 9: e11. - PMC - PubMed
    1. McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599–3726. - PubMed
    1. Virani SS, Alonso A, Aparicio HJ, et al.. Heart Disease and Stroke Statistics—2021 update: a report from the American Heart Association. Circulation 2021; 143(8): e254–e743. - PubMed

MeSH terms